Thank you, Jeff. Good morning, everyone, and thanks for joining us for today’s call. With me are Dr. Nicholas Borys, Celsion's Chief Medical Officer; and Jeffrey Church, of course, from whom you just heard, our Chief Financial Officer. As always, we are delighted to have the opportunity to update you on our progress and answer your question. And for those of you know me you can probably tell from my voice, I am fighting a cold, so please bear with me, we have got a lot to talk about and I'll try to keep the volume up. I’d like to start by saying once again that our fundamentals are sound, our progress is significant, and our excitement is palpable as the achievement of several important milestones we reported during the second quarter, milestones that continue to drive momentum both in and outside of the clinic. Our corporate goals remain unchanged and that is to develop novel, innovative, simple therapeutic solutions to address complex unmet medical needs, all the while pursuing long-term value for our shareholders. We do so with a great deal of focus on two primary clinical programs. The first is, the Phase III OPTIMA study. We’re working to rapidly advance the evaluation of our heat sensitive liposomal formulation of doxorubicin, that’s ThermoDox, for the treatment of newly diagnosed primary liver cancer patients. With over 850,000 incidents, primary liver cancer or HCC or hepatocellular carcinoma as its known, as you know, is the world's largest unmet medical need remaining in oncology. Our second and equally important work is in ovarian cancer. Leveraging our clinical development expertise, we've expanded our product pipeline to include the emerging science of immunotherapy. Our novel IL-12, that’s interleukin-12 gene mediated product candidate GEN-1 is now being evaluated exclusively in the OVATION study of newly diagnosed Stage III and Stage IV ovarian cancer patients. With both these programs treating patients in first line, success with either will establish both the significant advance in medicine and as you can imagine a substantial return to our shareholders. It’s worth repeating what I said just a moment ago and what I’ve said repeatedly during our prior calls, the fundamentals of our company are sound, without question are sound. Let me give you three reasons to believe. First, based on the data from 285 patients in the prior HEAT study, a highly de-risked Phase III OPTIMA study of ThermoDox plus optimized RFA, that’s RFA conducted for 45 minutes in newly diagnosed HCC patients is on track and on budget. The study is being conducted, I might say in a most professional and highly efficient manner with all of the major costs and heavy lifting behind us. We have active support from some of the most respected researchers and important institutions in the liver cancer world, with over 60 active clinical sites recruiting patients, 14 regulatory authorities from across the globe including Europe, North America, and Asia, and all the major HCC markets have reviewed and approved the OPTIMA study protocol. We have engaged internationally recognized world-class CROs and data management teams to ensure good clinical practice, ICH compliance, protocol adherence, and high quality data analytics. We are enrolling patients in line with our budget projections and feel confident that 550-patient enrollment requirement will be met mid next year. Bottomline, we have less than one year from completing enrollment and approximately five to six quarters for the first look at efficacy data. We have a proven and highly reliable supply chain with three redundant contract manufacturing organizations, that’s CMOs, registered and capable of producing ThermoDox in all regions of the world, providing a cost structure that ALBA guarantees high gross margins, regardless of the country or the local economy. And finally, the study’s independent Data Monitoring Committee just recently completed a preplanned review of the first 275 or 50% of the patients randomized in the trial as of April. Based on the assessment of safety, data quality, protocol compliance, and trial risk, the DMC unanimously recommended that the study continue without revision, I doubt that the DMC also commended the company for the rate of enrollment in the study with the potential to significantly expand the use of RFA and HCC. So, with virtually no operational risk and all the major costs behind us, we now look forward to study completion and data readout, and if you believe the many analyses supporting OPTIMA conducted by the company and by others, including an independent analysis of the OS data conducted by the National Institutes of Health, that’s the NIH, and you have to agree that our chances for success in this very important study are quite good. Second reason to believe is GEN-1 in the OVATION study has shown clear signs of biological activity and is showing early signs, and that’s early -- that that significant trends of clinical benefit. The Phase Ib dose escalating study evaluating our innovative gene mediated IL-12, that’s interleukin-12 immunotherapy know as GEN-1 in newly diagnosed ovarian cancer patients has completed enrollment with 15 evaluable patients. Clinical findings from the study will be presented by our lead investigator, Dr. Premal Thaker, Professor of Medicine at Washington University in St. Louis, at the 2017 ASCO Conference. Recently, translational data from the study was reviewed with leading immuno -oncology experts at the Roswell Park Cancer Institute. The translational data has shown that production of therapeutic IL-12 in this patient population is dose dependent. There appears to be a clear relationship between dose and activation of key elements of the immune system, particularly the cytokine interferon-gamma, the protein responsible for tumor specific T-cell activation and trafficking. Importantly, early clinical findings appear to tie this translational data with a margin negative resections that are reported in all of the patients treated at the highest dose cohort. Third reason to believe, while we operate with virtually no mistakes or surprises as you know, our cost structure is lean and our spending is efficient. We continue to operate with a small staff supplemented with highly professional contract research organizations. Our future spending on average will be approximately $1.3 million per month, that’s approximately $15 million per year to conduct two major clinical studies, global Phase III study that we just talked about in our advance clinical trials in newly diagnosed ovarian cancer patients. I would say it can’t get much better than that. So to summarize, Phase III OPTIMA study is on track, OVATION is complete, and showing exciting potential for GEN-1, and we have a cost structure, the envy of our industry. So I’ll guide you that our fundamentals are not sound, we have got a work that is not of significance, because if we are right looking at the potential for $1 billion market opportunities in both indications. Now I would like to go on a little bit more detail starting with ThermoDox. And just to repeat, the Phase III OPTIMA study is now over 60% enrolled, on track to completed enrollment of 550 patients during the second quarter of next year. Our target population is newly diagnosed HCC patients. The primary endpoint is overall survival. The study is 80% powered to show a 33% reduction in the risk of death. If achieved, ThermoDox will be -- will represent the only non-surgical curative option for intermediate HCC patients. That’s a single administration of ThermoDox plus RFA, in many cases performed in an outpatient setting, which potentially could be a curative treatment. The hypothesis for OPTIMA -- the OPTIMA study is supported with statistically significant but not preplan, I repeat, but not preplan statistically significant subgroup data from our prior HEAT study, 701 patient evaluation of ThermoDox in combination with RFA. The OPTIMA study designed -- is derived from 285 patients from the HEAT study whose single lesion was treated with RFAs standardized for greater than 45 minutes in this large well-bonded, well-balanced subgroup represented over 40% of the HEAT study patients, a group that we followed for over three years, we see that treatment with a combination of ThermoDox and standardized RFA, that’s RFA for more than 45 minutes, provided an average 54% reduction -- risk improvement in overall survival. The hazard ratio in this analysis was 0.65 with a p equal to 0.02. Simply put, this translates into a greater than two-year survival benefit for the ThermoDox over the optimized RFA-only group and after 80 months, the median overall survival for ThermoDox group still had not been reached and this population historically, median time to death in this population is about 36 months and our study was 57 months, like the core compare group -- for comparable group treated with RFA for 45 minutes. Now these conclusions and observations are not hours long. As I mentioned, the NIH conducted independent analysis of all single lesion patients, more than 60% of the study population and concluded that the longer after heating times when combined with ThermoDox resulted in a statistically significant improvement in overall survival. Now it’s not true for the RFA alone, so the RFA without ThermoDox. So quality measure also reviewed by the DMC was compliance with the minimum 45 minute RFA treatment specified in the protocol, rest about this compliance rate, so I am pleased to report you that there has been 99% plus compliance rate with the specific requirement. In addition to maintaining our focus on quality, execution of the OPTIMA study, we are also highly focused on the commercial opportunity for ThermoDox which is led by our regulatory strategy. ThermoDox has received FDA Fast Track Designation which provides among other things priority review. ThermoDox has been granted orphan drug designation for primary liver cancer in both the U.S. and Europe, which extents market exclusivity for seven years and 10 years, respectively, in these major revenue markets. Based on prior discussions and subject to a successful trial, we have designed the study to enroll sufficient number of patients from which raise the country to support registrational filings in U.S., Europe, China, South Korea, Taiwan and Vietnam among others. The China FDA, that’s the CFDA and from Celsion in a face to face meeting and if the ongoing Phase III OPTIMA study successful the trial could serve as the basis for direct regulatory filing in China without the need for prior approval in the U.S. or Europe, which is typically required. This will allow, as I have pointed out before, the company to accelerate its plans for regulatory filing in China and if approved provide for significantly earlier launch date in China than it was originally expected. Why is this important? While China represents, perhaps, most significant market opportunity for ThermoDox globally. As 50% of the 850,000 new cases diagnosed each year originate in China is 425,000 approximately. Moving to HCC and this -- in that country and this mark future largest market for pharmaceuticals in the world, I would say, safe to say that we are well-positioned. I’d now like to turn the GEN-1 for little bit more detail here also our immuno-oncology candidate developed on our TheraPlas platform. GEN-1 is a gene-mediated immuno-therapeutic which recruits the entirety of the immune system to fight malignancy. GEN-1 active agent is a DNA plasmid coded for the cytokine interleukin-12, as we mentioned, IL-12 plasmid is incorporated into a non-viral nanoparticle delivery system, that delivery system known as TheraPlas. When administered locally into a body cavity like the peritoneum of the bladder or even a cavity that's been created by the surgical removal of a tumor mass, nanoparticles invade surrounding cells and take over the metabolic machinery then turning each cells into a mini factories for the sustained local production of IL-12. Our first indication for GEN-1 is ovarian cancer, for patients newly diagnosed with advance -- with this advanced malignancy there is less than 45% chance of five years survival. One of the major reasons is diagnosis is made in patients are symptomatic at Stages III and IV with the cancer metastasis. In previous trials this patient population -- in this patient population GEN-1 has been used either as a monotherapy or in combination with chemotherapy with some promising results. As indicated earlier, Celsion's first trial in this indication, that’s when we sponsored after acquiring the GEN-1 asset, we called the OVATION study, is now fully enrolled, clinical findings and translational data being analyzed with the final review of all the data by scientific and Medical Advisory Committee in September. OVATION study enrolled 15 valuable newly diagnosed Stage III and Stage IV ovarian cancer patients, all patients presented with heavy disease burden prior to debulking surgery patients were treated with standard platinum and taxane, the goal of which is to improve surgical outcome by shrinking the tumor reducing the accompanied fluid known as ascites. Through this regimen we added eight weekly cycles of GEN-1. Following treatment with GEN-1 patient's then receive interval of debulking surgery. So I would like to summarize the early, I can’t say, early, but remarkable nonetheless results that we have seen so far and we will continue to update you with this information as it becomes available. Of the 14 valuable patients treated in the entire trial we saw 100% disease control rate, 86% objective response rate as measured by RECIST criteria, two patients demonstrated a complete response, 10 patients a partial response and two patients demonstrated stable disease of their cancer. Of the five patients treated in the highest dose cohort there was 100% objective response rate, with one complete response and four partial responses. All 14 patients had successful resections with tumors with nine patients that 64% having an R0 resection, which indicates -- R0 indicates a microscopically margin-negative resection in which no growth or microscopic tumor remains in the tumor bed. Of the five patients treated at the highest dose cohort, all five patients 100% experience in R0 surgical resection, seven of the eight patients 87% in the highest two dose cohorts experienced an R0 resection. All patients experienced a dramatically clinically significant decrease that was over 90% in the cancer antigen 125 protein that’s CA-125 protein levels as of the most recent follow-up and with the average decline for all patients treated at 97%, remarkable 97%. CA-125 used to monitor certain cancers during and after treatment. CA-125 is present in greater concentrations in ovarian cancer cells and other cells. Now what clinically significant here is a 50% reduction charges compared to we had over 97% average decline in CA-125 50% reduction is considered clinically meaningful. Of the seven patients who received GEN-1 treatment over one year ago and are being followed, only one patient's cancer has progressed after almost 12 months, it’s 11.7 months. This compares favorably to the historical median progression free survival of 12 months for newly diagnosed patients with Stage III and IV ovarian cancer. Of the remaining six patients who have been on this study for over year, their PFS is over 16 months with the longest progression free patient at 22.4 months. So we also just reported the latest translational data for 12 to 15 patients, which indicated convincing evidence of IL-12 for gene transfer and immune system activity. Data from the remaining three patients will be incorporated in September and reviewed by our Scientific Advisory Committee. A few weeks ago, we reported that translational data was -- this translational data was reviewed with leading immune-oncology experts in Roswell Park Cancer Institute and I will summarize as follows. The treatment-related changes in immune system activating cytokines like interferon-gamma and pro-tumor VEGF levels followed a dose-dependent trend and were predominantly in the peritoneal fluid compartment with little or no changes observed in the patients' systemic circulation. We saw pronounced decreases in the density of immunosuppressive T-cell signals like the T-Reg cell like the FoxP3 in PDL-1 and increases in CD8 cells in the tumor microenvironment. The ratio of CD8 cells to immunosuppressive cells was increased by approximately 75%. It was increased in approximately 75% of patients, suggesting an overall shift in the immune tumor environment from immunosuppressive to pro-immune stimulatory, an increase in the rate of CD8 to immunosuppressive T-cell populations is a leading indicator and believed to be a good predictor of improved overall survival. These translational research findings demonstrate that GEN-1 in ovarian cancer patients is biologically active and promotes a pro-immune T-cell population dynamic in the tumor microenvironment. More importantly, these distinct immunological changes in the local disease environment appear to translate into clinical benefit and warrant the continued development of GEN-1 as we will do. Now to summarize GEN-1 and ovarian cancer patients is biologically active, appears to have an immuno-stimulatory effect in the peritoneal fluid in a dose-dependent manner and promotes a pro-immune T-cell activity in the tumor tissue itself. So our next step in our clinical strategy our following review by our Scientific Advisory Board will be to outline on our Phase II program for GEN-1, which could likely continue in the current population of newly diagnosed patients, although what considering the alternative in platinum resistant patients, but we will make a decision following the review by our scientific advisory group. Following that, we of course, will submit our protocol for Phase II program with the NDA hopefully before the end of the fourth quarter. So with that, those are my prepared remarks. I will now turn the call over to Jeff to review our financial results. Jeff?
